On May 12, the US Department of Justice (DOJ) announced that Perfectus Aluminum Inc., Perfectus Aluminum Acquisitions LLC, and four affiliated warehousing companies agreed to one of the highest customs fraud settlements ever: a $549.5 million resolution of civil False Claims Act (FCA) allegations that they knowingly evaded antidumping and countervailing duties (AD/CVD) on aluminum extrusions imported from China.
In the latest episode of Five Questions, Five Answers, host Birgit Matthiesen is joined by ArentFox Schiff colleagues Jackson David Toof and Mario A. Torrico for a conversation on the False Claims Act (FCA), its origins, and its continued importance as a tool to combat fraud against the federal government.
On April 24, the US Attorney’s Office for the Eastern District of Tennessee announced a $2.1 million settlement with Echelon Fitness Multimedia, LLC, resolving False Claims Act (FCA) allegations of undervaluation leading to the underpayment of duties.
False Claims Act Investigations & Litigation attorneys Jacques Smith, Pat Naples, and John Keblish authored a piece for Chief Healthcare Executive on the key regulatory developments and emerging areas of risk in cybersecurity-specific False Claims Act (FCA) settlements.
On April 10, the US Department of Justice (DOJ) announced that International Business Machines Corporation (IBM) agreed to pay more than $17 million to resolve allegations that it violated the False Claims Act (FCA) by failing to comply with anti-discrimination requirements as set forth in Title VII of the Civil Rights Act of 1964.
ArentFox Schiff’s Pat Naples discusses with Medical Economics the US Centers for Medicare & Medicaid Services’ (CMS) expanded anti‑fraud enforcement and its impact on health care providers.
The False Claims Act (FCA) is the single-most powerful tool for rooting out fraud against the US government, and any nonprofit that receives federal funds should ensure compliance is integrated into its programs to avoid the severe penalties that can come with FCA violations.
Pat Naples was quoted on a recent appeal to the US Supreme Court about a Ninth Circuit interpretation of the False Claims Act’s prohibition on qui tam complaints that are “substantially the same” as previously disclosed allegations.
Health Care Industry Co-Leader Nadia Patel was quoted on Johnson & Johnson’s Janssen Products LP unit’s appeal to the Third Circuit Court of Appeals to overturn the 2025 jury $1.6 billion verdict — the largest False Claims Act (FCA) judgment in history.
Welcome to the March 2026 issue of “As the (Customs and Trade) World Turns,” our monthly newsletter where we compile essential updates from the customs and trade world over the past month. We bring you the most recent and significant insights in an accessible format, concluding with our main takeaways — aka “And the Fox Says…” — on what you need to know.
As we continue to move through 2026, the life sciences landscape is shaped by a convergence of regulatory, enforcement, and market access developments that demand heightened attention from industry stakeholders.